- ticket title
- Leaving the hospital early can double the odds of going back
- U.S. Medicare plans to track CAR-T cancer therapy outcomes
- Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients
- Asthma classes in school may help reduce attacks
- France suggests glyphosate exit could be even slower than planned
A Nestle logo is pictured on a coffee factory in Orbe, Switzerland May 31, 2018. REUTERS/Denis Balibouse
(Reuters) – The health science unit of Nestle SA would pay $ 98 million to increase its stake in Aimmune Therapeutics Inc, the drug developer for food allergies said on Monday.
The latest investment raises Nestle’s ownership of Aimmune to about 19 percent. The companies also extended their two-year strategic collaboration to develop therapies for food allergy by another two years, Aimmune said.
Reporting by Tamara Mathias in Bengaluru